Elvira Kamenetsky, MD
Neurology · Brooklyn, NYNPI 1275563165
Payments from drug & device makers
Across 255 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$999
- Amneal Pharmaceuticals LLC$607
- Amgen$483
- Kyowa Kirin, Inc.$385
- UCB, Inc.$323
- Lilly USA, LLC$265
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$200%
- Food & beverage$5,510100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $999 |
| Amneal Pharmaceuticals LLC | 26 | $607 |
| Amgen | 20 | $483 |
| Kyowa Kirin, Inc. | 15 | $385 |
| UCB, Inc. | 15 | $323 |
| Lilly USA, LLC | 11 | $265 |
| Pfizer | 9 | $237 |
| Scilex Pharmaceuticals Inc. | 10 | $218 |
| Otsuka America Pharmaceutical, Inc. | 8 | $199 |
| E.r. Squibb & Sons, L.L.C. | 10 | $161 |
| Lundbeck LLC | 7 | $160 |
| Teva Pharmaceuticals USA, Inc. | 9 | $157 |
| Johnson & Johnson | 7 | $155 |
| Avanir Pharmaceuticals, Inc. | 7 | $141 |
| Arbor Pharmaceuticals, Inc. | 9 | $137 |
| Neurocrine Biosciences, Inc. | 4 | $109 |
| SK Life Science, Inc. | 4 | $91 |
| MDD US Operations, LLC | 5 | $74 |
| Amarin Pharma, Inc. | 3 | $66 |
| Adamas Pharmaceuticals, Inc. | 3 | $61 |
| Medtronic | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Boston Scientific | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $46 |
| Vertical Pharmaceuticals, LLC | 2 | $35 |
| Almatica Pharma LLC | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Novartis | 1 | $24 |
| Assertio Therapeutics, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
How this compares
$5,530 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 143 | $176,207 |
| NamzaricMemantine Hcl/Donepezil Hcl | 207 | $125,294 |
| RytaryCarbidopa/Levodopa | 188 | $123,627 |
| RebifInterferon Beta-1a/Albumin | 11 | $115,890 |
| GraliseGabapentin | 287 | $103,283 |
| Emgality PenGalcanezumab-Gnlm | 132 | $94,751 |
| OngentysOpicapone | 109 | $88,147 |
| ZtlidoLidocaine | 198 | $81,233 |
| NourianzIstradefylline | 32 | $76,522 |
| Nurtec OdtRimegepant Sulfate | 67 | $75,250 |
| Memantine Hcl ErMemantine Hcl | 1,092 | $75,111 |
| QuliptaAtogepant | 65 | $68,997 |
| NeuproRotigotine | 59 | $54,924 |
| KeppraLevetiracetam | 54 | $50,549 |
| RexultiBrexpiprazole | 30 | $41,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Namzaric, Qulipta | $999 | $370,497415 claims |
| Amneal Pharmaceuticals LLCRytary | $607 | $123,627188 claims |
| Almatica Pharma LLCGralise | $28 | $103,283287 claims |
| PfizerNurtec Odt, Lyrica, Dilantin | $237 | $95,745102 claims |
| UCB, Inc.Neupro, Vimpat | $323 | $93,559104 claims |
| Neurocrine Biosciences, Inc.Ongentys | $109 | $88,147109 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $218 | $81,233198 claims |
| Kyowa Kirin, Inc.Nourianz | $385 | $76,52232 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $199 | $41,58130 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $137 | $36,64152 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $141 | $31,02025 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $20 | $14,03711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.
Other neurology in Brooklyn
- Idan SharonBrooklyn$2.1M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.